717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials

BACKGROUND: In the United States, CABP is the second most common cause of hospitalization and a leading cause of infectious death. Patients with chronic obstructive pulmonary disease (COPD)/asthma or diabetes are at risk for CABP and associated mortality. Similarly, patients with underlying cardiac...

Full description

Saved in:
Bibliographic Details
Published in:Open Forum Infect Dis
Main Authors: Schranz, Jennifer, Goldberg, Lisa, Das, Anita F, Alexander, Elizabeth, Moran, Gregory J, Sandrock, Christian, Shorr, Andrew F, Gelone, Steven P
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811254/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.785
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items